Compare ProShares UltraPro Short QQQ ETF (SQQQ) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro Short QQQ ETF vs TransMedics Group Inc — how do they compare? ProShares UltraPro Short QQQ ETF trades at $40.58, while TransMedics Group Inc trades at $73.5 (market cap $2.54B). Which is the better fit depends on your goals.
| SQQQ | TMDX | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $97.60 | $150.42 |
52-Week Low | $36.31 | $61.99 |
Market Cap | — | $2.54B |
Enterprise Value | — | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SQQQ trades at $42.68, down 0.26% on the day, with a bullish technical signal from moving averages but neutral oscillators. As a leveraged inverse ETF, it aims to deliver -3x the daily return of the Nasdaq-100, making it a tactical tool for hedging or short-term bearish bets rather than a long-term investment. Recent news highlights its role in protecting QQQ holdings but warns of severe erosion from daily resets.
The outlook for SQQQ is highly speculative, suited only for experienced traders timing tech sector declines. Key risks include volatility decay and reliance on accurate market timing, with long-term performance showing near-total loss since inception. It offers no fundamental value like earnings or dividends, serving purely as a hedging instrument.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
